Arrowhead Pharmaceuticals (NASDAQ:ARWR) Issues Earnings Results, Beats Expectations By $0.18 EPS

Arrowhead Pharmaceuticals (NASDAQ:ARWR) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.18, FiscalAI reports. Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The company had revenue of $73.74 million during the quarter, compared to analyst estimates of $73.84 million. During the same quarter last year, the business posted $2.75 EPS. The firm’s revenue for the quarter was down 86.4% on a year-over-year basis.

Here are the key takeaways from Arrowhead Pharmaceuticals’ conference call:

• REDEMPLO launch is outperforming expectations with >400 prescriptions written (~30 new scripts/week, >10% switches), accelerating refills, positive payer interactions, a U.S. WAC of $45,000/year, and regulatory approvals in Canada, China, Australia plus a CHMP positive opinion for the EU.
• Several high?impact clinical catalysts are imminent — top?line Q3 readouts for SHASTA?3/4 and MUIR?3 (plozasiran SHTG) to support an sNDA, first clinical data for ARO?DIMER?PA in Q3, and initial ARO?MAPT CNS platform data end?Q3/early?Q4, with additional ARO?INHBE/ARO?ALK7 updates in H2 2026.
• Financial and business?development moves strengthen optionality — concurrent financings ($700M convertible notes + $230M equity) plus other inflows left Arrowhead with nearly $1.8 billion in cash/investments, and the ARO?PNPLA3 license to Madrigal provides $25M upfront and up to $975M in milestones plus royalties.
• Q2 results show a net loss of $132.7M (vs prior?year quarter that included a one?time Sarepta gain), operating expenses of ~ $215M and only about $1M of derived net product sales, reflecting heavy ongoing R&D and commercialization spending.

Arrowhead Pharmaceuticals Stock Down 1.5%

Shares of Arrowhead Pharmaceuticals stock traded down $1.19 on Thursday, reaching $77.95. The stock had a trading volume of 2,337,541 shares, compared to its average volume of 1,792,252. The company has a 50 day moving average price of $64.30 and a 200 day moving average price of $60.36. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29. Arrowhead Pharmaceuticals has a 1 year low of $12.44 and a 1 year high of $79.48. The stock has a market capitalization of $10.92 billion, a P/E ratio of 50.95 and a beta of 1.28.

Insider Buying and Selling

In other news, CFO Daniel Joseph Apel sold 13,095 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total value of $934,328.25. Following the transaction, the chief financial officer owned 162,905 shares of the company’s stock, valued at $11,623,271.75. The trade was a 7.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total transaction of $750,000.00. Following the completion of the sale, the insider owned 226,958 shares of the company’s stock, valued at $17,021,850. This trade represents a 4.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 33,095 shares of company stock worth $2,326,228. Insiders own 3.60% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. iSAM Funds UK Ltd acquired a new stake in Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $29,000. Kestra Advisory Services LLC acquired a new stake in Arrowhead Pharmaceuticals in the 4th quarter worth approximately $144,000. Smartleaf Asset Management LLC boosted its stake in Arrowhead Pharmaceuticals by 71.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,903 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 1,211 shares in the last quarter. Vise Technologies Inc. acquired a new stake in Arrowhead Pharmaceuticals in the 4th quarter worth approximately $268,000. Finally, Quadrant Capital Group LLC acquired a new stake in Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $140,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ARWR has been the subject of a number of research analyst reports. Chardan Capital lifted their price objective on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. The Goldman Sachs Group lifted their price objective on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, January 7th. Morgan Stanley upgraded shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $78.00 to $100.00 in a report on Tuesday, April 21st. JPMorgan Chase & Co. initiated coverage on shares of Arrowhead Pharmaceuticals in a report on Friday, May 1st. They set an “overweight” rating and a $88.00 price objective for the company. Finally, Piper Sandler reiterated an “overweight” rating and set a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $84.20.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.